In this study, the combined intervention of EA and SFN in SAMP8 mice demonstrated that EA and SFN could inhibit the disease process of sarcopenia in mice by activating the AMPK/Sirt1/PGC-1α pathway. Here, PPARGC1A is linked to sarcopenia.